Ergomed (ERGO)

 

ERGO Share PerformanceMore

52 week high216.90 28/02/17
52 week low117.00 16/09/16
52 week change 66.00 (55.23%)
4 week volume402,308 27/07/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

CEL-SCI Corporation issues restricted shares

RNS Number: 5035O Ergomed plc 21 August 2017 PRESS RELEASE FOR IMMEDIATE RELEASE CEL-SCI Corporation issues restricted shares to Ergomed for partial settlement of receivable London, UK - 21 August 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company dedicated to the provision of specialised services to the pharmaceutical indu...

Ergomed's partner to resume Phase 3 study of Multikine

Ergomed said it has noted that its co-development partner CEL-SCI has confirmed the US Food and Drug Administration ...

FDA removal of hold on Ph3 trial with Multikine

RNS Number: 9319N Ergomed plc 14 August 2017 PRESS RELEASE Ergomed notes announcement by co-development partner, CEL-SCI, of FDA removal of clinical hold on Phase 3 clinical trial with Multikine in head and neck cancer London, UK - 14 August 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a specialised pharmaceutical services and dr...

Ergomed schedules interim results

Ergomed, a specialised pharmaceutical services and drug development company, will announce its results for the six mont...

Notice of Results

RNS Number: 8501N Ergomed plc 14 August 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Notice of interim results London, UK - 14 August 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a specialised pharmaceutical services and drug development company, will announce its Interim Results for the six months ended 30 June 2017 on Monday...

Ergomed completes study recruitment ahead of schedule

Ergomed has completed recruitment for its phase IIb proof-of-concept study for PeproStat, its innovative new coagulant, o...

Recruitment complete early for Phase IIb study

RNS Number: 8231L Ergomed plc 24 July 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Ergomed completes Phase IIb study recruitment six months ahead of schedule for its innovative coagulant PeproStat - Top line results expected in Q4 2017, six months earlier than anticipated - Faster than expected recruitment reflects Ergomed's strong CRO capabilities L...

Investor Meeting

RNS Number: 0817K Ergomed plc 04 July 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Investor meeting London, UK - 4 July 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, is today hosting an investor meeting at it...

Fundamental DataMore

P/E ratio142.692
EPS1.3
Dividend yield0 %

Equity Research (ERGO)

equity development
Ergomed Plc
08/05/2017
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. Aeterna Zentaris, a co-development partner of...
equity development
Ergomed Plc
12/04/2017
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. 2016 perfectly highlighted the strengths of the...
equity development
Ergomed Plc
25/01/2017
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. The recent period end update for Ergomed confirmed...

Latest discussion posts More

  • great news,,,,boom

    buy
    14-Aug-2017
    one4all
  • Results webinar

    If you would like to hear management present the preliminary results for the year ended 31 December 2016 for Ergomed we will be hosting a webinar on Wednesday 29th March at ...
    22-Mar-2017
    equity_dev
  • See management present

    If you would like to hear Stephen Stamp, Chief Finance Officer, present on behalf of Ergomed he will be appearing at our next investor forum on the evening of Wednesday 25th of ...
    17-Jan-2017
    equity_dev

Users' HoldingsMore

Users who hold Ergomed also hold..
TREATT36%
IQE27%
INSPIRED ENERGY27%
LENOVO27%
TRITAX BIG BOX27%

Codes & Symbols

ISINGB00BN7ZCY67
SymbolsERGO, LSE:ERGO, ERGO.L, ERGO:LN, LON:ERGO, XLON:ERGO